[ad_1]
KUALA LUMPUR: The Ministry of Health will review the first dengue vaccination in the world in the midst of the controversy that it has worsened the disease in some patients and caused the death of children in the Philippines.
Dr. Lee Boon Chye, Deputy Minister of Health the government was awaiting research results on whether the Dengvaxia vaccine is beneficial.
"We are not only trying to reduce dengue cases, but we also need to look at this in terms of profitability," he said. a press conference on the sidelines of the third Asia-Dengue Summit, Thursday 5 July.
Dr. Lee said that approval of new vaccines must be guided by three principles: safety, efficiency and cost-effectiveness.
Dr. Lee said that if the government chooses to use it or not, a study will be conducted first on its economic viability.
Dengvaxia is developed by the French pharmaceutical company Sanofi Pastuer.
Professor Datuk Zulkifli Ismail, chairman of Anising, said that he had not been certified that deaths in the Philippines were directly caused by the vaccine.
"We want to see what is the real cause of death," he said. He added that there were currently two other dengue vaccines in the pipeline, but they were still in the research phase.
Meanwhile, Dr. Lee reported that dengue cases and deaths have decreased in the last two years.
He said that in 2016 and 2017, dengue cases decreased by 16% and 17% respectively, while mortality dropped from 29% to 25%.
Dr. Lee reported in 2018 a total of 32,435 dengue cases with 53 deaths. reported from January to June 30 compared to the same period in 2017 where 49,726 cases with 100 deaths were reported.
Dr. Lee expressed concern that dengue cases could increase in June and July, as well as in December. the results in people traveling from one loc to the other.
[ad_2]
Source link
